BU-NOT-SET

CONTACT US
Global expansion in the CDMO field
  • Industry trends
Eyes
Insight
Fixed dose combinations - for improved patient compliance
  • Drug product
mini-tablets
Fact sheet
The current state of contract manufacturing
  • Industry trends
Eyes
Insight
The potential impact of Brexit on patient safety
  • Industry trends
Eyes
Insight
EU FMD: After the deadline
  • Manufacturing
Eyes
Insight
The importance of supply chain security
  • Manufacturing
Eyes
Insight
ADC development: setbacks and key developments
  • Drug substance
Lab equipment
Insight
Cytotoxic unsaturated electrophilic compounds commonly target the ubiquitin proteasome system
  • Drug substance
Eyes
Insight
CDMO trends: Drug development and industry consolidation
  • Industry trends
Eyes
Insight
Brochure
  • Corporate
Explore Recipharm's Full Service Offering
Insight
  • Drug product
Successful drug development
Insight
  • Manufacturing
How CDMOs can help reduce the risk of counterfeit medicines entering the supply chain
Insight
  • Drug product
Tackling complexity in scale-up
Insight
  • Industry trends
Navigating COVID-19 – the role of CDMOs
Insight
  • Drug product
Best pharmaceutical dosage forms
Insight
  • Analytical chemistry
Taking an innovative approach to analytical chemistry
Insight
  • Analytical chemistry
Recipharm and Oncopeptides collaborate in the development of Melflufen for the treatment of multiple myeloma
Insight
  • Drug product
Excipients for orally disintegrating products